Kirtland Hills Capital Management LLC Has $420,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Kirtland Hills Capital Management LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,137 shares of the medical research company’s stock after selling 69 shares during the quarter. Kirtland Hills Capital Management LLC’s holdings in IQVIA were worth $420,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IQV. FMR LLC grew its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the 3rd quarter worth about $147,683,000. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Finally, KBC Group NV grew its holdings in IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after acquiring an additional 250,458 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Price Performance

IQVIA stock opened at $190.98 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company’s 50 day moving average price is $199.41 and its two-hundred day moving average price is $215.63. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $33.63 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.